Aroa Biosurgery

    OverviewSuggest Edit

    Aroa Biosurgery is a medical device company focused on soft-tissue repair. It commercializes regenerative tissue substitutes for medical indications based on its proprietary Endoform extracellular matrix (ECM) platform.
    HQAuckland, NZ
    Employee Ratings4.4

    Latest Updates

    Employees (est.) (Jan 2022)148(+3%)
    Cybersecurity ratingCMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Aroa Biosurgery

    James Agnew

    James Agnew

    Chief Financial Officer
    Steve Engle

    Steve Engle

    Independent, Non-Executive Director
    Jim McLean

    Jim McLean

    Independent, Non-Executive Director and Chair
    Simone von Fircks

    Simone von Fircks

    Vice President - Operations
    John Pinion

    John Pinion

    Independent, Non-Executive Director
    Brian Ward

    Brian Ward

    Founder and Chief Executive Officer, Director
    Show more

    Aroa Biosurgery Office Locations

    Aroa Biosurgery has an office in Auckland
    Auckland, NZ (HQ)
    2 Kingsford Smith Place, Māngere
    Show all (1)

    Aroa Biosurgery Financials and Metrics

    Summary Metrics

    Founding Date


    Aroa Biosurgery Cybersecurity Score

    Cybersecurity ratingPremium dataset



    SecurityScorecard logo

    Aroa Biosurgery Online and Social Media Presence

    Embed Graph

    Aroa Biosurgery News and Updates

    Global Permanent Artificial Skin Market 2020-2024 | Evolving Opportunities with AVITA Medical Ltd. & Aroa Biosurgery Ltd. | 17000 + Technavio Reports

    NEW YORK, Sept. 27, 2021 /PRNewswire/ -- The permanent artificial skin market is poised to grow by USD 4.41 bn during 2020-2024, progressing at a CAGR of 19% during the forecast period, according to Technavio. The report offers an up-to-date analysis and to know exact growth variance and...

    Aroa Biosurgery Blogs

    Aroa Biosurgery Half Yearly Report H1 FY22

    Highlights H1 FY22 product revenue (unaudited) grew 110% on H1 FY21 and 39% on H2 FY21, to NZ$17.2 H1 FY22 product revenue (unaudited) grew 110% on H1 FY21 and 39% on H2 FY21, to NZ$17.2million on a constant currency basis.1 H1 FY22 product revenue (unaudited) was $17.7 million on a reported basis. …

    Real-World Data shows Aroa Biosurgery’s Endoform™ Natural achieves significantly improved wound closure for Diabetic Foot Ulcers compared to traditional collagen dressings

    Highlights A retrospective analysis of real-world data published in the ‘International Wound Journal’ compared the wound closure times for diabetic foot ulcers treated with either Endoform™ Natural (1150 wounds) or collagen/ORC (1072 wounds). The data was analyzed to evaluate the median time for wou…

    Aroa Biosurgery’s Myriad Matrix receives validation for reconstruction of tissues affected by Pilonidal Sinus Disease

    Highlights• AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in Journal of Wound Care.• Study of six patients shows 100% success rates from use of Myriad Matrix™ as an implant during surgical reconstruction of soft tissues affected by Pilonidal Sinus Disea…

    Aroa Biosurgery June 2021 4C – Commentary

    HIGHLIGHTS US medical procedure numbers continue to reflect a positive trend supporting improved sales momentum. AROA maintains its published product sales guidance of $30-33 million (up 39-53% on FY21) and gross margin above 70%. Net cash outflow from operations was NZ$2.7 million for the June quar…

    Aroa Biosurgery releases FY2021 Annual Report

    Aroa Biosurgery is pleased to release its first Annual Report since successfully completing its IPO and Admission onto the ASX in July 2020. The full report is available to view on the Investors page or click to download here.

    Aroa Biosurgery March 2021 4C – Commentary

    HIGHLIGHTS H2 FY21 product revenues (unaudited) grew 16% on H2FY20 to $13.8m on a constant currency basis (i.e. eliminating impact of exchange rate fluctuations). FY21 full year product revenue was $21.5m, exceeding the Company’s forecast of $21.0m. Total revenue (unaudited) of $22.3m for FY21. Base…
    Show more

    Aroa Biosurgery Frequently Asked Questions

    • When was Aroa Biosurgery founded?

      Aroa Biosurgery was founded in 2008.

    • Who are Aroa Biosurgery key executives?

      Aroa Biosurgery's key executives are James Agnew, Steve Engle and Jim McLean.

    • How many employees does Aroa Biosurgery have?

      Aroa Biosurgery has 148 employees.

    • Who are Aroa Biosurgery competitors?

      Competitors of Aroa Biosurgery include GreenBone Ortho, Graftys and Tenex Health.

    • Where is Aroa Biosurgery headquarters?

      Aroa Biosurgery headquarters is located at 2 Kingsford Smith Place, Māngere, Auckland.

    • Where are Aroa Biosurgery offices?

      Aroa Biosurgery has an office in Auckland.

    • How many offices does Aroa Biosurgery have?

      Aroa Biosurgery has 1 office.